AI Article Synopsis
- A 14-year-old girl with primary hyperparathyroidism (PHPT) presented with high calcium levels but surprisingly low serum intact parathyroid hormone (PTH).
- She had a confirmed parathyroid adenoma and showed varying PTH levels between different testing methods: low on routine assays but high on intraoperative tests.
- The discrepancy suggests that the adenoma produces an altered PTH molecule that standard tests can't detect, highlighting the importance of using multiple assay methods for accurate diagnosis in hyperparathyroidism cases.
Article Abstract
Context: Primary hyperparathyroidism (PHPT) is usually associated with hypercalcemia and inappropriately elevated serum PTH.
Objective: Our objective was to identify the reason(s) for a low serum intact PTH in a child with PHPT.
Subject And Methods: A 14-yr-old Caucasian girl presented with pancreatitis, nephrolithiasis, hypercalcemia ranging from 13.2 to 17.5 mg/dl, and a low serum intact PTH. She had an ultrasound and technetium-99m-sestamibi scintigraphy confirming the presence of a parathyroid adenoma.
Results: The preoperative serum intact PTH assays performed at Quest Diagnostics, Nichols Institute, were low even after serial dilutions, whereas the intraoperative turbo PTH assay was elevated at 3618 pg/ml. C-terminal and cyclase-activating PTH assays for PTH were also elevated. PTH gene sequence analysis performed from DNA extracted both from the parathyroid adenoma and the patient's peripheral blood leukocytes was negative for a mutation in the PTH gene sequence.
Conclusions: The contrasting values on the intact PTH assay and the turbo PTH assay suggest that the adenoma was producing an aberrant PTH molecule that was not detected by the routine intact PTH assay. Because there was no change in PTH gene sequence, this could be indicative of a posttranslational change in the PTH molecule that would not be recognized solely by DNA sequencing. Therefore, a low or normal PTH measurement against the backdrop of clinical and biochemical hyperparathyroidism needs measurement with a variety of assays.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206518 | PMC |
| http://dx.doi.org/10.1210/jc.2011-0247 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Postanesthesia Care Unit Parathyroid Hormone-Based Protocol for Managing Postthyroidectomy Hypocalcemia.
J Surg Res
January 2025
Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address:
Introduction: Hypocalcemia occurs in 20%-40% of total thyroidectomy cases, traditionally requires 1-2 ds of hospitalization for management. This study examines the extent of hypocalcemia following a postanesthesia care unit (PACU) parathyroid hormone (PTH)-based protocol after outpatient thyroidectomy.
Methods: Patients who underwent total or completion thyroidectomy for non-Graves' disease at a single institution between December 2015 and September 2023 were included.
Case report: Ectopic production of intact parathyroid hormone (iPTH) by malignoma mimicking primary hyperparathyroidism.
Front Oncol
December 2024
Department of Nephrology, St. Georg Hospital, Leipzig, Germany.
Background: Malignant hypercalcemia is usually caused by osteolytic processes of metastases, production of parathormone-related peptide, or secretion of 1,25-dihydroxyvitamin D. Ectopic PTH (parathyroid hormone) production by malignancy is very unusual.
Methods: Case report and review of the literature.
Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease.
J Bone Metab
November 2024
Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Chronic kidney disease (CKD) often leads to mineral and bone disorders (CKD-MBDs), which are nearly universal in patients undergoing dialysis. CKD-MBD includes abnormal calcium-phosphate metabolism, vascular and soft tissue calcification, and bone abnormalities (renal osteodystrophy [ROD]). Bone fragility in CKD occurs due to low bone mass and poor bone quality, and patients with CKD have higher fracture and mortality rates.
View Article and Find Full Text PDFHypoparathyroidism in adults with iron overload diseases (IOD): evidence of a subclinical phenotype.
Endocrine
December 2024
Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Purpose: To explore the prevalence of hypoparathyroidism (HPT), overt and subclinical, in a cohort of adults with Iron Overload Diseases (IOD). Secondary aim was to test the calcium (Ca)-to-phosphorus (P) ratio performance in identifying HPT.
Methods: Single-center, prospective, case-control study.
Background: Chronic kidney disease (CKD) is a global public health burden with significantly increasing mortality. Chronic kidney disease leads to various complications, including anemia, cardiovascular complications, salt and water retention, metabolic acidosis, electrolyte disorders, and chronic kidney disease-mineral and bone disorder (CKD-MBD), amongst which CKD-MBD is a particularly important complication that develops early.
Materials And Methods: In the present study, various biochemical analytes were assessed for their significance in monitoring the CKD-MBD in different stages of CKD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!